Enveric Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph Edward Tucker
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4851 Tamiami Trail North Naples FL United States of America 34103
- IPO Date
- May 4, 2015
- CIK
- 0000890821
- Website
- enveric.com
- Similar Companies
- Business
- Enveric Biosciences, Inc. (NASDAQ: ENVB) develops novel neuroplastogenic small-molecule therapeutics targeting depression, anxiety, addiction disorders, and other neuropsychiatric conditions; its Psybrary discovery platform generates proprietary psychedelic-inspired molecules designed to promote neuroplasticity without hallucinogenic effects; lead candidate EB-003 advances in preclinical development as a potential first-in-class neuroplastogen for severe mental health disorders, with plans for first-in-human trials in 2026; the EVM401 series of mescaline derivative compounds expands the pipeline for addiction, neuropsychiatric, neurodegenerative, and cognitive applications; additional Psybrary-derived candidates, including EVM301 and EVM201 series, support out-licensing opportunities. The company out-licenses non-core assets, including the EVM201 program featuring EB-002 to MycoMedica Life Sciences for up to $62 million in milestones plus royalties, and patented Cannabinoid-COX-2 conjugate compounds to Restoration Biologics for joint disease treatment with potential milestones up to significant values; recent financing includes $2.2 million from warrant exercises to fund EB-003 development and IP expansion; new U.S. patents cover EVM301, EB-003, and EVM401 series; in September 2025, Enveric relocated its corporate headquarters from Naples, Florida, to Cambridge, Massachusetts, to access biotech talent, collaborations, and capital in the Greater Boston hub while maintaining offices in Calgary, Canada. Founded through a 2020 reverse merger and operating from Calgary, Alberta, Canada origins, Enveric targets patients with unmet needs in mental health via U.S.-based development and global licensing partnerships.
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
What's Going On With Enveric Biosciences Stock On Friday?
Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum
Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
Enveric Biosciences Announces Registration of Five Trademarks
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules